About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in San Antonio | 12,572 Studies Near You | Clareo Health

Clinical Trials LocationsSan Antonio

Clinical Trials in San Antonio

Discover 12,572 clinical trials near San Antonio, Texas. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 1781-1800 of 12,572 trials

RECRUITINGPhase 4< 1 mile

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

NCT05936580

Recombinant factor VIII for the prevention of bleeding in women/girls with haemophilia A undergoing major surgery

Octapharma28 participantsStarted Apr 2026

San Antonio, Texas, United States • Helsinki, Finland • Chambray-lès-Tours, France +12 more locations

Active Not RecruitingPhase 2< 1 mile

A Study in Patients With Mixed Dyslipidemia

NCT06497127

A Phase 2 in Patients With Mixed Dyslipidemia

Mixed Dyslipidemia

Shanghai Argo Biopharmaceutical Co., Ltd.145 participantsStarted Feb 2024

Daphne, Alabama, United States • Mobile, Alabama, United States • Boca Raton, Florida, United States +11 more locations

Find Trials by Condition in San Antonio

Breast Cancerin San Antonio Lung Cancerin San Antonio Prostate Cancerin San Antonio Colorectal Cancerin San Antonio Melanomain San Antonio Leukemiain San Antonio Lymphomain San Antonio Pancreatic Cancerin San Antonio Ovarian Cancerin San Antonio Brain Cancerin San Antonio

Data from ClinicalTrials.govTerms

COMPLETEDPhase 2< 1 mile

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

NCT03816891

Study of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis (PN).

Prurigo NodularisPruritis

Genentech, Inc.240 participantsStarted Mar 2019

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Little Rock, Arkansas, United States +83 more locations

Active Not RecruitingPhase 1< 1 mile

Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07336940

The goal of this clinical trial is to learn about the safety and tolerability of ENV-294 in adults with moderate to severe atopic dermatitis. It may also learn about the changes ENV-294 may have on the severity of atopic dermatitis symptoms. The main questions it will answer are: * Is ENV-294 safe and well tolerated in adults with moderate to severe atopic dermatitis? * Is there an impact on the severity of atopic dermatitis symptoms when participants take ENV-294? Researchers will review the atopic dermatitis present at the beginning of the study against the atopic dermatitis present at the end of the study. Participants will: * Take drug ENV-294 once every day for 28 days * Visit the clinic weekly for 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug ENV-294

Atopic Dermatitis (AD)

Enveda Therapeutics16 participantsStarted Sep 2025

Fremont, California, United States • Louisville, Kentucky, United States • College Station, Texas, United States +2 more locations

Not Yet Recruiting< 1 mile

Efficacy and Feasibility Trial of a Portable Near Infra-Red Hematoma Imager (NIRD-HI)

NCT07338383

Traumatic Brain Injury (TBI) is a leading cause of death and disability among military personnel, Veterans, and civilians. One of the most dangerous complications of moderate-to-severe TBI is intracranial hemorrhage (ICH). If not identified and treated promptly, ICH can rapidly lead to worsening neurological damage or death. Current diagnostic tools, such as CT scans, are highly effective but impractical for battlefield or resource-limited environments due to their large size and infrastructure dependency. The Near-Infrared Detection-Head Imaging (NIRD-HI) system is an innovative, noninvasive device using Near-Infrared Spectroscopy (NIRS) to identify abnormal blood accumulation. Unlike traditional tools, NIRD-HI is compact, lightweight, and portable, making it suitable for remote or austere settings. By dynamically imaging the brain, it generates 3D visualizations that pinpoint the size and location of bleeds, including complex bilateral injuries. This offers a significant improvement over current point-of-injury technologies that lack the resolution to reliably diagnose all forms of ICH. This study supports the FY24 Combat Readiness Medical Research Program by advancing battlefield diagnostic and triage capabilities. The research will: * Evaluate NIRD-HI's accuracy compared to CT imaging. * Assess feasibility in real-world acute care settings. * Investigate its ability to monitor changes in ICH over time. These objectives address the military's need for tools that improve rapid diagnosis and decision-making during emergencies. Implementing this research can revolutionize TBI management. For Service Members, NIRD-HI promises a field-ready solution for early detection, enabling faster intervention and more effective triage. By reducing diagnostic delays, it could save lives and prevent long-term complications. Furthermore, the system supports prolonged field care by providing continuous monitoring of evolving injuries. The benefits extend to civilian healthcare, particularly in rural or underserved areas lacking advanced imaging. This accessibility can improve trauma care outcomes for millions, reduce the burden on healthcare systems, and provide equitable distribution of life-saving technology. By addressing gaps in battlefield medicine, this project aims to enhance medical readiness and improve survivability in the most challenging environments.

Traumatic Brain InjuryIntracranial HemorrhagesCombat Casualty Care+1 more

The Geneva Foundation80 participantsStarted Jan 2026

San Antonio, Texas, United States

RECRUITINGNA< 1 mile

Neural Connectivity During Therapy for Adolescent PTSD

NCT05423444

Posttraumatic stress disorder in adolescence impairs neurobiological networks underlying cognitive, social and emotional skills. Neuroimaging research that seeks to identify the neural mechanisms of treatments for PTSD could lead to novel treatments, but progress has been slow using current methods. The proposed study uses an innovative approach to identify neural mechanisms of specific phases of trauma-focused therapy for youth with PTSD, allowing a new understanding of brain changes associated with the process of therapy.

PTSDAdolescentPsychological Trauma

The University of Texas Health Science Center at San Antonio180 participantsStarted Nov 2022

San Antonio, Texas, United States

RECRUITINGPhase 3< 1 mile

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

NCT05099770

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT/rilparencel injections given 12 weeks (-14 days to +28 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.

Type 2 Diabetes MellitusChronic Kidney Diseases

Prokidney685 participantsStarted Jan 2022

Tucson, Arizona, United States • Beverly Hills, California, United States • Glendora, California, United States +83 more locations

RECRUITINGNA< 1 mile

Field Shield Wound Dressing Study

NCT07337616

This study is to compare the Field Shield Wound Dressing (FSWD) as a treatment for burn wounds to a standard of care burn wound dressing to evaluate healing, infection, pain/discomfort, and deepening of wound over time.

Burn Wounds - Partial Thickness (2nd Degree)

KeriCure Medical40 participantsStarted May 2025

Phoenix, Arizona, United States • San Antonio, Texas, United States

COMPLETEDPhase 389 miles

A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

NCT04486716

A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis who are transitioning from aCD20 mAb therapy

Relapsing Multiple Sclerosis

Novartis Pharmaceuticals111 participantsStarted Oct 2020

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Pomona, California, United States +17 more locations

TERMINATEDPhase 2167 miles

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04987307

The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC). Participants will be randomized to receive 1 of 3 efavaleukin alfa doses or placebo during a 12-week induction period. Participants who complete the 12-week induction period will have the option to enter an exploratory long-term treatment period for up to 40 weeks (total of up to 52 weeks of treatment) if, in the opinion of the investigator, they may benefit from continued treatment. During the long-term period, participants randomized to efavaleukin alfa will remain on the same efavaleukin alfa blinded dose; participants randomized to placebo who achieved clinical response at week 12 will remain on placebo; and placebo non-responders (ie, participants randomized to placebo who did not achieve clinical response at week 12) will receive efavaleukin alfa in a blinded manner during continued treatment. All participants will complete a safety follow-up visit 6 weeks after their last dose of investigational product.

Ulcerative Colitis

Amgen221 participantsStarted Jan 2022

Dothan, Alabama, United States • Homewood, Alabama, United States • Mesa, Arizona, United States +197 more locations

COMPLETEDPhase 1/2190 miles

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

NCT02264613

This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with WT TP53.

Solid TumorLymphomaPeripheral T-Cell Lymphoma

Aileron Therapeutics, Inc.142 participantsStarted Oct 2014

Birmingham, Alabama, United States • Duarte, California, United States • Denver, Colorado, United States +10 more locations

RECRUITINGPhase 1190 miles

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

NCT05614739

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.

Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms

Eli Lilly and Company535 participantsStarted Jan 2023

Tucson, Arizona, United States • Duarte, California, United States • Los Angeles, California, United States +81 more locations

Active Not RecruitingPhase 2190 miles

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

NCT07335601

A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.

MASH - Metabolic Dysfunction-Associated Steatohepatitis

Madrigal Pharmaceuticals, Inc.120 participantsStarted Dec 2025

La Jolla, California, United States • Los Angeles, California, United States • San Francisco, California, United States +12 more locations

COMPLETEDNA238 miles

Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure

NCT04452149

The ALLEVIATE-HF study is a prospective, randomized, controlled, blinded, multi-site, interventional, investigational device exemption (IDE) pivotal study. The purpose of the study is to demonstrate the safety and efficacy of a patient management pathway that utilizes an integrated device diagnostic-based risk stratification algorithm to guide patient care in subjects with NYHA class II and III heart failure, and to demonstrate the safety of the Reveal LINQ™ system and procedure in the study population.

Heart Failure NYHA Class IIHeart Failure NYHA Class III

Medtronic Cardiac Rhythm and Heart Failure826 participantsStarted Sep 2020

Mesa, Arizona, United States • Jonesboro, Arkansas, United States • Mission Viejo, California, United States +50 more locations

Active Not RecruitingPhase 2253 miles

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

NCT00602667

RATIONALE: In this study a combination of anti-cancer drugs (chemotherapy) is used to treat brain tumors in young children. Using chemotherapy gives the brain more time to develop before radiation is given. The chemotherapy in this study includes the drug methotrexate. This drug was an important part of the two clinical trials which resulted in the best survival results for children less than 3 years of age with medulloblastoma. Most patients treated on this trial will also receive radiation which is carefully targeted to the area of the tumor. This type of radiation (focal conformal or proton beam radiotherapy) may result in fewer problems with thinking and learning than radiation to the whole brain and spinal cord. PURPOSE: This clinical trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system tumors.

Brain and Central Nervous System Tumors

St. Jude Children's Research Hospital293 participantsStarted Dec 2007

Palo Alto, California, United States • San Diego, California, United States • Saint Paul, Minnesota, United States +3 more locations

Active Not RecruitingPhase 3253 miles

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

NCT03148418

This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) and who continue to receive study treatment at the time of the parent-study closure and do not have access to the study treatment locally are eligible for continued treatment in the extension study. Dosing regimen for a given participant and indication will be the same or equivalent to the respective parent study protocol. Study treatment in the extension study can continue until disease progression or beyond if the patient continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; patient non-compliance; or study termination by the Sponsor, whichever occurs first.

Hoffmann-La Roche382 participantsStarted Sep 2017

Scottsdale, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +167 more locations

COMPLETEDPhase 2507 miles

A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

NCT05569759

This was a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis received zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period allowed participants to receive zetomipzomib (KZR-616) for an additional 24 weeks of treatment.

Autoimmune Hepatitis

Kezar Life Sciences, Inc.24 participantsStarted May 2023

Phoenix, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +21 more locations

TERMINATEDPhase 2881 miles

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

NCT05172596

This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple myeloma

Multiple Myeloma

Novartis Pharmaceuticals146 participantsStarted Mar 2022

Palo Alto, California, United States • Atlanta, Georgia, United States • Boston, Massachusetts, United States +33 more locations

COMPLETEDPhase 31012 miles

Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

NCT05630001

The purpose of the study was to find out if iptacopan is effective and safe in adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who switched from their current standard of care treatment (eculizumab or ravulizumab) to study treatment, iptacopan/LNP023.

Paroxysmal Nocturnal Hemoglobinuria

Novartis Pharmaceuticals52 participantsStarted Apr 2023

Duarte, California, United States • Los Angeles, California, United States • Miami Lakes, Florida, United States +20 more locations

Active Not Recruiting1062 miles

Liver Cirrhosis Network Cohort Study

NCT05740358

Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-person visits will include questionnaires, physical exams, imaging, and sample collection.

CirrhosisCirrhosis, LiverCirrhosis Early+9 more

Northwestern University1,222 participantsStarted Nov 2022

La Jolla, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +11 more locations

PreviousPage 90 of 629Next

Diabetes

in San Antonio

Heart Diseasein San Antonio